Inventiva (NASDAQ:IVA) Sees Large Volume Increase – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw strong trading volume on Thursday . 174,831 shares were traded during trading, an increase of 151% from the previous session’s volume of 69,777 shares.The stock last traded at $3.8110 and had previously closed at $4.05.

Analyst Upgrades and Downgrades

IVA has been the subject of several research analyst reports. HC Wainwright upped their price target on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Wolfe Research raised Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. Finally, Guggenheim increased their price target on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $17.57.

Inventiva Stock Performance

The stock has a 50 day moving average of $5.24 and a 200 day moving average of $4.18.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Creative Planning purchased a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,000 shares of the company’s stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.